• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Immune-mediated cholangitis: is it always nivolumab's fault?免疫介导的胆管炎：这总是纳武单抗的错吗？
Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5.
2
Response to "Immune-mediated cholangitis: is it always nivolumab's fault?".对《免疫介导的胆管炎：总是纳武单抗的错吗？》的回应
Cancer Immunol Immunother. 2018 Aug;67(8):1329-1330. doi: 10.1007/s00262-018-2163-7. Epub 2018 Apr 26.
3
Three cases of immune cholangitis related to anti-programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer.三例与用于治疗非小细胞肺癌的抗程序性细胞死亡和程序性细胞死亡配体药物相关的免疫性胆管炎。
Eur J Cancer. 2019 Jul;115:107-110. doi: 10.1016/j.ejca.2019.04.022. Epub 2019 May 24.
4
Development of mild drug-induced sclerosing cholangitis after discontinuation of nivolumab.停用纳武单抗后发生轻度药物性硬化性胆管炎。
Eur J Cancer. 2019 Jan;107:93-96. doi: 10.1016/j.ejca.2018.11.021. Epub 2018 Dec 13.
5
Nivolumab for the treatment of Japanese patients with advanced metastatic non-small cell lung cancer: a review of clinical trial evidence for efficacy and safety.纳武利尤单抗治疗晚期转移性非小细胞肺癌的日本患者：疗效和安全性临床试验证据的综述。
Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618801167. doi: 10.1177/1753466618801167.
6
A case of nivolumab-related cholangitis and literature review: how to look for the right tools for a correct diagnosis of this rare immune-related adverse event.尼伏鲁单抗相关性胆管炎 1 例并文献复习：如何寻找正确的工具以正确诊断这种罕见的免疫相关不良事件。
Invest New Drugs. 2018 Feb;36(1):144-146. doi: 10.1007/s10637-017-0484-6. Epub 2017 Jun 20.
7
Lymphocyte involvement in nivolumab-induced autoimmune myositis.淋巴细胞参与纳武单抗诱导的自身免疫性肌炎。
Pathology. 2019 Aug;51(5):555-557. doi: 10.1016/j.pathol.2019.02.006. Epub 2019 Jun 15.
8
Hepatobiliary and Pancreatic: Nivolumab-related cholangiopathy.肝胆胰：与纳武利尤单抗相关的胆管病。
J Gastroenterol Hepatol. 2018 Oct;33(10):1695. doi: 10.1111/jgh.14136. Epub 2018 Apr 29.
9
Nivolumab-Induced Fulminant Immune-Related Colitis Despite Infliximab in a Patient With NSCLC.一名非小细胞肺癌患者在使用英夫利昔单抗治疗期间出现纳武利尤单抗诱导的暴发性免疫相关性结肠炎
J Thorac Oncol. 2019 Mar;14(3):e49-e50. doi: 10.1016/j.jtho.2018.11.014.
10
Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient.一名长期缓解的非小细胞肺癌患者中广泛发生的纳武利尤单抗诱导的肠病
Clin Lung Cancer. 2018 Sep;19(5):e591-e596. doi: 10.1016/j.cllc.2018.04.013. Epub 2018 May 5.

引用本文的文献

1
Immunoglobulin G4 associated autoimmune cholangitis and pancreatitis following the administration of nivolumab: A case report.纳武单抗治疗后发生的免疫球蛋白G4相关性自身免疫性胆管炎和胰腺炎：一例报告
World J Clin Cases. 2022 Jul 16;10(20):7124-7129. doi: 10.12998/wjcc.v10.i20.7124.
2
Lessons to be Learnt from Real-World Studies on Immune-Related Adverse Events with Checkpoint Inhibitors: A Clinical Perspective from Pharmacovigilance.从免疫相关不良事件的真实世界研究中吸取的经验教训：药物警戒的临床视角。
Target Oncol. 2020 Aug;15(4):449-466. doi: 10.1007/s11523-020-00738-6.
3
Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.免疫检查点抑制剂的毒性：来自 FDA 不良事件报告系统的比例失调分析的新兴重点。
Target Oncol. 2019 Apr;14(2):205-221. doi: 10.1007/s11523-019-00632-w.
4
Response to "Immune-mediated cholangitis: is it always nivolumab's fault?".对《免疫介导的胆管炎：总是纳武单抗的错吗？》的回应
Cancer Immunol Immunother. 2018 Aug;67(8):1329-1330. doi: 10.1007/s00262-018-2163-7. Epub 2018 Apr 26.

本文引用的文献

1
Bile duct obstruction in a patient treated with nivolumab as second-line chemotherapy for advanced non-small-cell lung cancer: a case report.纳武利尤单抗二线化疗治疗晚期非小细胞肺癌后发生胆管梗阻：病例报告。
Cancer Immunol Immunother. 2018 Jan;67(1):61-65. doi: 10.1007/s00262-017-2062-3. Epub 2017 Sep 14.
2
Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.免疫疗法毒性管理：ESMO诊断、治疗及随访临床实践指南
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142. doi: 10.1093/annonc/mdx225.
3
Imaging and clinicopathological features of nivolumab-related cholangitis in patients with non-small cell lung cancer.尼伏单抗相关胆管炎在非小细胞肺癌患者的影像学和临床病理特征。
Invest New Drugs. 2017 Aug;35(4):529-536. doi: 10.1007/s10637-017-0453-0. Epub 2017 Mar 20.
4
Nivolumab-induced cholangitic liver disease: a novel form of serious liver injury.纳武单抗诱导的胆管炎肝病：一种新型严重肝损伤形式。
Ann Oncol. 2017 Mar 1;28(3):671-672. doi: 10.1093/annonc/mdw649.
5
EASL Clinical Practice Guidelines: management of cholestatic liver diseases.欧洲肝脏研究学会临床实践指南：胆汁淤积性肝病的管理
J Hepatol. 2009 Aug;51(2):237-67. doi: 10.1016/j.jhep.2009.04.009. Epub 2009 Jun 6.

Immune-mediated cholangitis: is it always nivolumab's fault?

作者信息

Gelsomino Francesco, Vitale Giovanni, Ardizzoni Andrea

机构信息

Medical Oncology Unit, Policlinico S. Orsola-Malpighi, University of Bologna, Via Albertoni 15, 40138, Bologna, Italy.

出版信息

Cancer Immunol Immunother. 2018 Aug;67(8):1325-1327. doi: 10.1007/s00262-018-2159-3. Epub 2018 Apr 5.

DOI:10.1007/s00262-018-2159-3
PMID:29623342
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11028150/
Abstract
摘要